上海医药：多西环素胶囊获美国FDA批准文号

Core Insights - Shanghai Pharmaceuticals announced that its subsidiary, Changzhou Pharmaceutical Factory, has received FDA approval for the abbreviated new drug application (ANDA) for Doxycycline capsules, which are primarily used for treating inflammatory lesions (papules and pustules) of rosacea in adult patients [1] Financial Summary - As of the announcement date, Changzhou Pharmaceutical Factory has invested approximately RMB 10.83 million in research and development for Doxycycline capsules [1] - The projected sales revenue for Doxycycline capsules in the U.S. for 2024 is approximately $130 million [1]